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UCP22) regulates glucose-stimulated insulin secretion in pancreatic beta-cells. UCP2
content, measured by calibrated immunoblot in INS-1E insulinoma cells (a pancreatic beta-cell model) grown
in RPMI medium, and INS-1E mitochondria, was 2.0 ng/million cells (7.9 ng/mg mitochondrial protein). UCP2
content was lower in cells incubated without glutamine and higher in cells incubated with 20 mM glucose,
and varied from 1.0–4.4 ng/million cells (2.7–14.5 ng/mg mitochondrial protein). This dynamic response to
nutrients was achieved by varied expression rates against a background of a very short UCP2 protein half-life
of about 1 h.
© 2008 Elsevier B.V. Open access under CC BY license.1. Introduction
Pancreatic beta-cells maintain glycaemic control by secreting
insulin in response to high glucose concentrations. Mitochondria
play an important role in glucose-stimulated insulin secretion (GSIS)
by coupling glucose oxidation to ATP production. Glucose oxidation
raises the mitochondrial protonmotive force and increases the ATP:
ADP ratio, leading to closure of ATP-sensitive potassium channels,
plasma membrane depolarisation, activation of voltage-gated calcium
channels, and an inﬂux of calcium that promotes exocytosis of insulin-
containing granules [1]. This acute phase of insulin secretion is
followed by a second sustained phase driven by mitochondrial and
cytosolic amplifying signals [2,3].
Uncoupling protein 2 (UCP2) attenuates insulin secretion by
regulated uncoupling, which lowers the mitochondrial protonmotive
force and the cytosolic ATP:ADP ratio. Ucp2 knockout in mice [4] or its
acute removal by siRNA knockdown in whole animals [5] and beta-
cell lines [6] improves GSIS, and overexpression of UCP2 in isolated
islets [7] or whole animals [8] attenuates GSIS. UCP2 activity may
coordinate the physiological response of beta-cells to ﬂuctuating
nutrient supply [9].
UCP2 content in beta-cells is regulated at the transcriptional and
translational levels. Ucp2 gene expression is upregulated by hyper-
glycaemia and hyperlipidaemia, via transcription factors includingse; GSIS, glucose-stimulated
ROS, reactive oxygen species;
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 license.sterol regulatory element binding protein 1c (SREBP 1c) [10], and
peroxisome proliferator-activated receptors PPAR-alpha [11] and
PPAR-gamma [12,13]. Cold exposure, acting via sympathetic nerve
stimulation and the PPAR-gamma coactivator PGC-1, can also increase
Ucp2 gene expression [14]. Repression of transcription, on the other
hand, has been shown to involve sirtuins [15,16] and interleukin IL-1-
beta [17]. In other cell types, Ucp2 mRNA levels do not necessarily
correlate with protein concentrations [18], because of translational
regulation. An upstream open reading frame inhibits translation of
Ucp2 mRNA, and inhibition can be overcome by glutamine [19,20].
UCP2 can also be regulated at the functional level; it is activated by
reactive oxygen species in beta-cell mitochondria [21] and beta-cells
[22], and inhibited by purine nucleoside di- and tri-phosphates [21].
Nothing is known about UCP2 protein degradation in beta-cells,
although in ovarian and granulosa cell lines, the half-life of UCP2 is
less than 1 h [23].
In the present paper we characterise the content and regulation of
UCP2 in INS-1E insulinoma cells, a widely used clonal rat pancreatic
beta-cell model. We show that UCP2 concentration varies 4–5-fold
depending on the composition of the growth medium, because of
translational and possibly transcriptional control. The half-life of UCP2
is about 1 h, allowing rapid and dynamic ﬂuctuations in the UCP2
content of the cells in response to nutrients in the medium.
2. Materials and methods
2.1. Sample preparation
All chemicals were from Sigma-Aldrich or Gibco unless stated
otherwise. INS-1E cells were maintained in RPMI medium as
Fig. 1. UCP2 standardisation. (A) Lanes 1 and 2: puriﬁed or unpuriﬁed inclusion body
rUCP2. Purity was calculated from the intensity of the UCP2 band divided by the
intensity of the whole lane. rUCP2 runs at a higher molecular weight than native UCP2
(lane 4) owing to its N-terminal appendage. Lanes 3 and 4: UCP2 antibody speciﬁcity as
veriﬁed by immunoblotting INS-1E cells following treatment with siRNA against UCP2
or a scrambled siRNA control. (B) Linearity of calibration standards. rUCP2 standards
were run on every gel (the immunoblot shows an example). After normalisation to the
densitometry signal for 600 pg rUCP2, the densitometry signal was proportional to
rUCP2 loaded. Values are means±SEM, n=12.
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Nunclon™ 500 cm2 trays were seeded at 2.5×105 cells/ml and grown
to approximately 90% conﬂuence. Following twowashes with ice-cold
SHE buffer (0.25 M sucrose, 20 mM HEPES (pH 7.4), 2 mM EGTA,
10 mM KCl, 1.5 mM MgCl2 and 0.1% (w/v) defatted bovine serum
albumin), cells were scraped off the trays and harvested by
centrifugation at 350 g (10 min, 4 °C), then aliquots were made for
cell UCP2 or mRNA quantiﬁcation or mitochondrial isolation.
Mitochondria were prepared from INS-1E cells as described in [25],
either with or without a protease inhibitor cocktail.
Mitochondria from rat and mouse tissues were isolated by
standard methods. Female Wistar rats (Charles River Laboratories,
UK) and Ucp2−/− [4] and wild-type sibling paired mice were 10–
12 months old. Ucp2 knockout was conﬁrmed by PCR analysis of the
Ucp2 locus and immunoblotting. Animals were housed at 21±2 °C,
humidity 57±5% with a 12 h light/dark cycle. Food and water were
available ad libitum. Home Ofﬁce Guidelines for the Care and Use of
Laboratory Animals (UK) were followed.
2.2. Quantiﬁcation of UCP2 protein
Recombinant UCP2 (rUCP2) protein standards were prepared by
subcloning, overexpression and puriﬁcation of rat UCP2. cDNA
containing the rat Ucp2 gene was from imaGenes (Berlin, Germany).
The complete UCP2 transcript was obtained by PCR using UCP2
forward (5′-CACCATGGTTGGTTTCAAGGCCACCGATGT-3′) and UCP2
reverse (5′-TCAAAAGGGTGCCTCCCGGGATTCATAGG-3′) primers. The
transcript beginning CACC was subcloned into pET100/D-TOPO
(Invitrogen, Paisley, UK) using the TOPO® cloning system according
to the manufacturer's instructions. This plasmid added an N-terminal
appendage (including a His6-tag) to the expressed protein. BL21 Star
transformed with pET100/D-TOPO containing Ucp2 were grown at
37 °C until OD600=0.5. Expression was induced using 1 mM IPTG for
6 h. Inclusion bodies containing rUCP2 were isolated as described [26]
and solubilised in 50 mM HEPES pH 7.4 containing 8 M urea and
25 mM DTT for 1 h at room temperature. The sample was diluted 10-
fold then puriﬁed using a HisTrap HP™ column (GE Healthcare, UK)
according to the manufacturer's instructions. The concentration of
eluted protein was determined by BCA protein assay (Pierce) and
purity was assessed by SDS PAGE. SDS PAGE, immunoblotting and
quantiﬁcation of UCP2 in cells and mitochondria were performed as
described in [6]. Where appropriate, membranes were stripped
(Restore™ Plus, Pierce) and reblotted for adenine nucleotide translo-
case (ANT), or stained with Gelcode® Blue reagent (Pierce) to quantify
protein. UCP2 (sc-6525) and ANT (sc-9300) antibodies were from
Santa Cruz Biotechnology, USA.
2.3. Quantiﬁcation of Ucp2 transcript
Total RNA was extracted from snap-frozen pellets of (0.5–1)×105
INS-1E cells using RNeasy kit (Qiagen) and cDNA was synthesised
using random hexamers and the Transcriptor First Strand cDNA
Synthesis Kit (Roche) according to the manufacturer's protocol. Ucp2
template was ampliﬁed (UCP2 forward: 5′-GATCTCATCACTTTCCCTC-
TAGACA-3′, UCP2 reverse: 5′-CCCTTGACTCTCTCCTTGG-3′, UCP2
probe: 5′-6CGCCAAAGTCCGGCTGCAGA0-3′) using a 7900HT Fast
Real-Time PCR System with Taqman Master Mix (ABI). Expression
was normalised to 18S rRNA (18S forward: 5′-CGGCTACCACATC-
CAAGGAA-3′, 18S reverse: 5′-GCTGGAATTACTGTGGCT-3′, 18S probe:
5′-6GAGGGCAAGTCTGGTGCCAG0-3′) under each condition.
2.4. UCP2 half-life
INS-1E were seeded at 3×105 cells/ml in 24-well plates (Falcon)
and used after 24 h in fully supplemented RPMI medium containing
2 mM, 10 mM or 20 mM glucose. Cells were treated with 10 μg/mlcycloheximide at time zero to arrest protein translation. At various
time points they were harvested by trypsinisation in RPMI containing
protease inhibitors and pelleted by centrifugation (800 g, 2 min). Cells
(or isolated mitochondria) were resuspended in gel loading buffer,
boiled for 5 min and vortexed vigorously. UCP2 content was
determined by immunoblot.
2.5. Data analysis
Data are presented as means±SEM or range. Differences were
tested for statistical signiﬁcance by one-way ANOVA applying
Dunnett's post hoc analysis. Values of Pb0.05 were considered
signiﬁcant.
Fig. 2. UCP2 content in INS-1E cells and mitochondria. INS-1E cells were incubated for 24 h in standard RPMI (containing 2 mM glutamine, 5% fetal calf serum and 10 mM glucose),
RPMI lacking glutamine or fetal calf serum or both, or RPMI containing 2 mM or 20 mM glucose. Cell aliquots were assayed for cell and mitochondrial UCP2 content and cell Ucp2
mRNA. (A) UCP2 protein quantiﬁed in whole cell lysates. Gel loading: 1×105 cells/lane. Values are means±SEM of averages of duplicate values from n=3 cell preparations (the
immunoblot shows an example). (B) UCP2 protein quantiﬁed in isolated mitochondria. Gel loading: 40 μg mitochondrial protein/lane. Values are means±range of averages of
triplicate values from n=2 cell preparations (the immunoblot shows an example). (C) Subsequent Coomassie staining of membranes from (B) with Gelcode® Blue conﬁrmed
equal protein loading. (D) Ucp2 mRNA measured using qPCR from total mRNA and standardised against 18S rRNA. Values are means±SEM of averages of duplicate values from
n=3 cell preparations. (E) Comparison of relative UCP2 protein and mRNA levels under different conditions. Values from A–C normalised to control. ⁎Pb0.05; ⁎⁎Pb0.01 compared
to #. Q, glutamine; FCS, fetal calf serum; Gluc, glucose.
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Fig. 3. UCP2 content in rodent tissue mitochondria. (A) UCP2 immunoblots of rat and
mouse mitochondria from different tissues. Mitochondrial protein loaded: 5 μg spleen,
40 μg liver, 30 μg kidney, 40 μg pancreas. (B) Quantiﬁcation of UCP2 in mitochondria
from rat tissues using rUCP2 standards. Values are means±range of averages of
duplicate values from n=2 mitochondrial preparations.
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3.1. Dynamic variation of UCP2 content
Characterisation of INS-1E cells has shown that they retain GSIS
and a high degree of differentiation, making them a good model of
pancreatic beta-cells [27]. Initial observations suggested that UCP2
content was high in INS-1E cells grown in standard RPMI medium,
but much lower in cells incubated in simple salts medium for 90 min
(C. Affourtit & M.D. Brand, unpublished observations). To investigate
why, we used immunoblotting calibrated with recombinant UCP2
standards to quantify UCP2 in cells and isolated mitochondria after
incubation of cells in different media.
Since INS-1E cells are derived from rat, we generated a rat
recombinant UCP2 standard. Use of a rat standard was important
for accurate quantiﬁcation, as the antibody (anti-human UCP2)
reacted about twice as strongly with recombinant human standards
than rat standards (not shown). By Gelcode® Blue stain, rUCP2 in
washed inclusion bodies was about 50% pure (Fig. 1A lane 2); this
was increased to about 80% by using a HisTrap column (Fig. 1A
lane 1); the purity was taken into account in the calibrations. The
speciﬁcity of the UCP2 antibody was veriﬁed by RNAi knockdown
of UCP2 in INS-1E cells (Fig. 1A lanes 3 and 4). rUCP2 was used on
each immunoblot to generate an internal calibration curve. Fig. 1B
shows that the densitometry signal was proportional to the rUCP2
loaded; all measurements were made within the linear range
shown.
The UCP2 content of cells grown in standard RPMI medium,
measured by calibrated immunoblot, was 2.0 ng/million cells (Fig. 2A,
control bar). The UCP2 content of mitochondria isolated from the
same cells was 7.9 ng/mg of mitochondrial protein (Fig. 2B, control
bar). By division, the mitochondrial content of the cells was therefore
250 μg mitochondrial protein/million cells. Assuming a mitochondrial
volume of 1 μl/mg protein and a cell volume of 2.4 μl/million cells
(estimated from themean diameter of trypsinised cells), mitochondria
therefore comprise 11% of the volume of an INS-1E cell.
Omission of glutamine from the medium resulted in decreases in
UCP2 in cells and mitochondria (Fig. 2A and B) without affecting Ucp2
mRNA levels (Fig. 2C). The relative changes in UCP2 protein and Ucp2
mRNA are shown in Fig. 2D. Protein content changed signiﬁcantly but
mRNA did not, suggesting that UCP2 is translationally controlled by
glutamine in INS-1E cells, in agreement with studies in other cells
[19,20]. Serum starvation had no effect on Ucp2mRNA, and although it
consistently lowered UCP2 protein levels, implying translational
control, this effect was not signiﬁcant (Fig. 2D).
Lowering glucose to 2 mM had no effect on UCP2 protein or mRNA,
but doubling glucose concentration to 20 mM increased protein levels
2-fold over control (Fig. 2D), and affected mRNA in the same direction,
although not signiﬁcantly, suggesting transcriptional control of Ucp2
mRNA by high glucose in INS-1E cells. This is explained by [28], where
increased glucose was shown to transcriptionally activate Ucp2with a
lack of reversibility of Ucp2mRNA levels when glucose in the medium
is changed from a higher to a lower concentration.
Between them, these interventions caused UCP2 concentrations to
vary 4–5-fold in 24 h, from 1.0–4.4 ng/million cells (2.7–14.5 ng/mg
mitochondrial protein). These mitochondrial concentrations are
hundreds of times lower than UCP1 in brown adipose tissue, and
20-fold lower than UCP3 in skeletal muscle [29]. To compare them to
UCP2 concentrations in other rat tissues, we analysed mitochondria
from rat spleen, liver, kidney and pancreas. Fig. 3A shows that the
antibody detected UCP2 in spleen, kidney and pancreas mitochondria
from wild-type mice and rats, but not in Ucp2−/− mice. Fig. 3B shows
the values for rat mitochondria, quantiﬁed as before. Levels of UCP2 in
INS-1E cells were similar to those in kidney and whole pancreas, and
20-fold lower than in spleen, previously reported to have the highest
UCP2 levels of any tissue [29].3.2. UCP2 has a short half-life in INS-1E cells
To investigate the role of protein degradation on the variation of
UCP2 levels, INS-1E cells were treated with cycloheximide to arrest
protein synthesis, and UCP2 levels were measured at different
times by immunoblotting. UCP2 was found to have a short half-life
of approximately 1 h (Fig. 4A, B), presumably allowing the dynamic
ﬂuctuations in UCP2 seen above and perhaps accounting for the
low abundance of this protein. This short half-life contrasts with
the much longer half-life of other members of the mitochondrial
carrier family, such as UCP1 (see [23,30]) and ANT (Fig. 4A).
Furthermore, the half-life of UCP2 does not appear to be
dependent on protein levels because doubling UCP2 content by
incubation of INS-1E cells with 20 mM glucose had no effect on
protein turnover, and expression of UCP1 and UCP2 in the same
yeast system still gives a much longer half-life for UCP1 (30 h)
than UCP2 (30 min) [23].
In contrast to whole cells, UCP2 levels were stable in isolated
mitochondria (Fig. 4C), implying that either the signal for degradation
or degradation itself occurs outside the mitochondrion.
Our work shows that owing to the short half-life (1 h) of UCP2,
incubating cells in simple salt media can result in lowUCP2 levels. This
work may explain the variability of UCP2-mediated effects in different
laboratories. Reassuringly, UCP2 is stable once mitochondria have
been isolated.
4. Conclusion
There is dynamic regulation of UCP2 concentration in INS-1E cells
that is characterised by fast rates of synthesis and degradation. UCP2
synthesis is under translational and probably transcriptional control
(as literature suggests for other cells [19,20,28]), and its dynamic
regulation is enabled by very rapid protein turnover. This highlights
the dynamic response of UCP2 concentration and perhaps activity to
changes in the nutrient supply, and sheds light on the ability of UCP2
Fig. 4. UCP2 half-life. (A) INS-1E cells were incubated for 24 h in RPMI containing 2 mM, 10 mM, or 20 mM glucose, then treated with 10 μg/ml cycloheximide to arrest protein
synthesis, harvested at the times shown and immunoblotted for UCP2. Stripped membranes were reblotted for ANT as a control (the lower immunoblot shows an example). Gel
loading: 1.5×105 cells/lane. (B) Cell UCP2 content (normalised to time zero in each condition) as a function of time after cycloheximide treatment. Values are means±SEM from n=4
mitochondrial preparations. (C) Mitochondriawere isolated from cells incubated for 24 h in standard RPMI, incubated in SHE buffer at 37 °C for various times then immunoblotted for
UCP2. Gel loading: 36 μg mitochondrial protein/lane. (D) Subsequent Coomassie staining of membranes from (C) with Gelcode® Blue conﬁrmed equal protein loading.
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cells from pancreatic islets [31], and whole animals [4,5].
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